Histone MacroH2A1/MacroH2A2 (C-Term) Monoclonal Antibody

MacroH2A proteins are variant histones that are enriched on inactivated X chromosomes and have roles in the maintenance of nuclear organization and heterochromatin architecture.{57292,57293,58069} MacroH2A1 is encoded by MACROH2A1 and can exist as two isoforms, macroH2A1.1 and macroH2A1.2, produced by alternative splicing, and macroH2A2 is encoded by MACROH2A2.{57293} MacroH2As are comprised of a histone fold, which is approximately 65% identical to canonical histone H2A, a basic linker, and a C-terminal non-histone macrodomain, which is unique to macroH2As and protrudes from the nucleosome core to recruit various co-factors.{58069,57292,57293} The non-histone region of macroH2A2 is 68% identical to that of macroH2A1.2, whereas the macrodomain of macroH2A1.1 is unique in that it can bind to ADP-ribose and ADP-ribosylated proteins.{57293,58069} Low levels of macroH2A1.1 are associated with poor prognosis in patients with lung or colon cancer, and loss of macroH2A2 expression is associated with earlier recurrence of lesions in patients with anal intraepithelial neoplasia (AIN).{58069,57294} MacroH2A1.2 expression is increased in highly proliferative cancer cell lines, but it can act as a tumor suppressor in melanoma and bladder cancer, indicating that its role in cancer is context-dependent. Cayman's Histone MacroH2A1/MacroH2A2 (C-Term) Monoclonal Antibody can be used for ELISA, immunocytochemistry (ICC), multiplex-based assay, and Western blot (WB) applications. The antibody recognizes the C-terminus of macroH2A1 and macroH2A2 independent of post-translational modifications (PTMs).